1. MASLD nomenclature and what establishes the diagnosis

MASLD is a category of steatotic liver disease defined by hepatic steatosis plus at least one cardiometabolic risk factor. It is a consensus nomenclature proposed by multiple societies in 2023, not a universal one-step renaming that makes every earlier NAFLD diagnosis interchangeable. The histologic threshold of steatosis is not a stand-alone self-diagnosis rule. Clinicians interpret imaging or histology alongside alcohol exposure, alternative liver diseases, and metabolic risk.

2. Steatosis, inflammation and fibrosis are different findings

The 2024 EASL–EASD–EASO guideline distinguishes steatosis from MASH with inflammation and liver-cell injury, fibrosis and cirrhosis. Fat seen on imaging does not establish a fibrosis stage. The guideline states that scores such as FIB-4 and liver stiffness tests cannot directly assess microscopic features such as ballooning or lobular inflammation. Ask whether a finding concerns fat, inflammation or scar tissue.

3. FIB-4 triage and its limits

The guideline uses FIB-4, based on age, AST, ALT and platelets, as a first step in assessing advanced-fibrosis risk. Below 1.3 is on the lower-risk side of its usual pathway, not proof of no fibrosis. Results from 1.3 to 2.67 require a follow-up pathway shaped by history, risk and resources, including possible elastography. Above age 65 the lower cutoff changes to 2.0; performance is poor below age 35. Diabetes and other clinical context also matter. This is a 2024 EASL pathway, not one testing policy for every country.

4. Hepatology expert perspective: guideline goals and evidence

The EASL–EASD–EASO practice guideline recommends sustained dietary and behavioral weight loss for adults with MASLD and overweight. Its targets are at least 5% to reduce liver fat, 7–10% to improve liver inflammation, and at least 10% to improve fibrosis. These are guideline goals drawn from clinical evidence, not guaranteed individual outcomes or diagnostic cutoffs. Care also addresses cardiovascular and metabolic risks and other liver conditions. When first-line risk assessment is elevated or indeterminate, clinicians may consider elastography or another secondary test; the decision depends on the patient and local pathway.

5. Connect a result to the next review

Collect “test and date showing steatosis / age / AST, ALT and platelet results with units used in the same assessment / reported FIB-4 / alcohol, metabolic conditions and medicines / responsible clinician and follow-up plan.” A fictional entry, “age 50, reported FIB-4 1.6, discussion of elastography pending,” is neither a cirrhosis diagnosis nor a completed test. Do not combine results from different dates or fill unknowns with normal values.

Ask which risk the score assessed, what additional-test or follow-up pathway applies, and who will review the result when. Meeting a weight-loss target is not a measured finding of improved fibrosis; record actual follow-up findings separately.

Sources